Skye BioscienceSKYE
SKYE
About: Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Employees: 16
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
300% more call options, than puts
Call options by funds: $84K | Put options by funds: $21K
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
50% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]
3% more funds holding
Funds holding: 73 [Q4 2024] → 75 (+2) [Q1 2025]
3.36% less ownership
Funds ownership: 83.09% [Q4 2024] → 79.73% (-3.36%) [Q1 2025]
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
45% less capital invested
Capital invested by funds: $71.3M [Q4 2024] → $39.3M (-$32M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$15
277%
upside
Avg. target
$15
277%
upside
High target
$15
277%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Jonathan Wolleben | 277%upside $15 | Market Outperform Reiterated | 24 Jun 2025 |
Financial journalist opinion
Based on 3 articles about SKYE published over the past 30 days
Positive
Seeking Alpha
4 days ago
Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing
Skye Bioscience's Nimacimab remains a promising peripheral CB1 antibody for obesity with lean-mass preservation and fewer GI issues. Nimacimab's Phase 2a topline is expected by Q3-Q4 2025, which is its next catalyst in the short term. Since Nimacimab can also help with GLP-1 non-responders or as a maintenance therapy, it shows an added potential as a combo therapy.
Neutral
GlobeNewsWire
2 weeks ago
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of its “Anatomy of Progress” nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association's (ADA) 85th Scientific Sessions held June 20-23, 2025, in Chicago, Illinois. The presentations are accessible at the following link.
Neutral
GlobeNewsWire
3 weeks ago
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it was selected to present new nimacimab data in its expanded preclinical model at the upcoming American Diabetes Association's (ADA) 85th Scientific Sessions. Skye will present in multiple forums at the ADA conference, which is being held June 20th – 23rd, 2025, at the McCormick Place Convention Center in Chicago, Illinois.
Positive
Zacks Investment Research
1 month ago
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Neutral
GlobeNewsWire
1 month ago
Skye Bioscience to Participate in Upcoming Investment Conferences
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences:
Positive
Proactive Investors
1 month ago
Arecor shares jump 10% on obesity drug partnership with Skye Bioscience
Shares in Arecor Therapeutics PLC (AIM:AREC) rose 10% in morning trading after the company announced a new development deal with US biotech group Skye Bioscience to improve the formulation of a mid-stage obesity drug. The Cambridge-based firm will apply its proprietary Arestat technology to create a more concentrated version of nimacimab, a monoclonal antibody that targets the CB1 receptor, which plays a role in appetite and metabolism.
Positive
Proactive Investors
1 month ago
Arecor partners with Skye Bioscience to improve formulation of obesity drug
Arecor Therapeutics PLC (AIM:AREC) has entered a development partnership with Skye Bioscience Inc (NASDAQ:SKYE), a US-based biotechnology group, to create a more concentrated formulation of an experimental obesity treatment, as drugmakers vie for a share of the fast-growing weight-loss market. The Cambridge-based company will use its proprietary Arestat technology to reformulate nimacimab, a monoclonal antibody developed by Skye that targets the CB1 receptor.
Neutral
GlobeNewsWire
1 month ago
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
Proprietary formulation technology being applied to potentially enhance properties of nimacimab Proprietary formulation technology being applied to potentially enhance properties of nimacimab
Neutral
GlobeNewsWire
1 month ago
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on May 7, 2025, the Board of Directors granted a non-qualified stock option award to purchase 100,000 shares of its common stock to one new non-executive employee under the Company's Amended and Restated 2024 Inducement Equity Incentive Plan (the “2024 Inducement Plan”). The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small molecule-based CB1 inhibitors, which both exhibited increasing dose-dependent brain penetration • This model predicts nimacimab's potentially superior therapeutic index, which is dependent on minimal brain exposure while maintaining sufficient peripheral inhibition SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, presented a clinical pharmacokinetic (“PK”) and pharmacodynamic (“PD”) model that underscores the fundamental relationship between biodistribution and efficacy of CB1 inhibitors at the annual European Congress on Obesity meeting. This model demonstrated that achieving strong peripheral CB1 inhibition is sufficient to achieve efficacy, including weight loss.
Charts implemented using Lightweight Charts™